摘要
宫颈癌是最常见的妇科恶性肿瘤,严重威胁女性健康,其发生与人乳头瘤病毒(HPV)的持续感染密切相关。随着分子生物学与免疫学研究的进展,HPV疫苗已在宫颈癌预防方面取得卓越成效,免疫治疗成为宫颈癌尤其是晚期及复发癌治疗的新模式。针对手术及放化疗治疗不理想的进展期或复发性宫颈癌,目前许多研究均在探索免疫治疗的安全性、效应性,主要研究方向包括标准治疗同期加用免疫治疗、单独使用免疫治疗、联合抗血管治疗或多种免疫治疗药物联用,以及新型HPV预防性疫苗的研究。本文对疫苗免疫治疗、过继细胞免疫治疗、树突状细胞免疫治疗和免疫检查点抑制剂等宫颈癌免疫治疗的进展进行综述。
Cervical cancer is the most common gynecological tumor and it is a serious threat to women’s health.The occurrence is closely related to the persistent infection of human papillomavirus(HPV).With the progress of molecular biology and immunology,HPV vaccine achieved excellent results in the prevention of cervical cancer,and immunotherapy became a new treatment model for cervical cancer,especially for advanced and recurrent cancer.Many studies are currently exploring the safety and effectiveness for the treatment of advanced or recurrent cervical cancer that is not ideal for surgery,radiotherapy and chemotherapy.The main research directions include standard treatment with immunotherapy simultaneously,or immunotherapy alone.This article briefly reviews the progress of cervical cancer immunotherapy such as vaccine immunotherapy,adoptive cell immunotherapy,dendritic cell immunotherapy and immune checkpoint inhibitors.
作者
张唯一
王铭洋
李亚里
Zhang Weiyi;Wang Mingyang;Li Yali(Department of Obestetrics and Gynecology,First Medical Center,Chinese PLA General Hospital,Beijing 100853,China)
出处
《中国医药》
2020年第12期1959-1962,共4页
China Medicine
关键词
宫颈癌
免疫治疗
人乳头瘤病毒疫苗
免疫检查点抑制剂
Cervical cancer
Immunotherapy
Human papillomavirus vaccine
Immune checkpoint inhibitors
